Preliminary Study On The Expression And Pathogenesis Of IL-17 In Bone Marrow Of Patients With Multiple Myeloma

Objective: to investigate the expression and pathogenesis of IL-17 in bone marrow blood of multiple myeloma(MM)patients.Methods: Double antibody enzyme-linked immunosorbent assay(ELISA)was used to detect the expression levels of IL-6,TNF-α,and IL-17 in bone marrow serum of 20 patients with multiple myeloma and 20 controls,and the correlation between IL-17 and IL-6 and TNF-α was analyzed by correlation analysis.The effect of IL-17 on the proliferation of multiple myeloma cells was tested by cell proliferation and toxicity test(CCK8)with different concentrations of IL-17.The morphological changes of RAW264.7 cells were observed by tartrate resistant acid phosphatase(TRAP)staining on the osteoclast precursors(RAW264.7 cell lines)treated with IL-17.RT-PCR was used to detect the expression of the corresponding RNA in the activation of RAW264.7 cells.Western blotting assay was used to detect the expression of key proteins in RAW264.7 cells during activation.Results: serum IL-17,IL-6 and TNF-α levels in MM patients were higher than those in the normal control group,and the difference was statistically significant(P < 0.05).There was a positive correlation between IL-17 and IL-6 and TNF-α levels(r =0.6045 and r=0.6275).Cell proliferation and toxicity assay confirmed that IL-17 can promote the proliferation of multiple myeloma cells.TRAP staining showed that IL-17 could induce differentiation of RAW264.7 cells into multicellular giant cells.RT-PCR and Western blotting were used to detect the expression of key RNA and protein in the activation process of osteoclast precursor cells(RAW264.7 cells).Conclusion:IL-17 is highly expressed in the bone marrow of patients with multiple myeloma and may be involved in the pathogenesis of MM.It can promote the proliferation of tumor cells and induce the activation of osteoclasts,leading to the aggravation of bone destruction.